Bristol-Myers Squibb (BMY) vs Gilead Sciences (GILD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Bristol-Myers Squibb (BMY) has outperformed Gilead Sciences (GILD) over the past year, gaining 33.7% versus a gain of 25.7%. Over five years, GILD leads with a +117.1% price change compared with +2.3% for BMY. Gilead Sciences is the larger company by market cap ($179.71 billion vs $120.37 billion), about 1.5 times the size.
On valuation, Bristol-Myers Squibb trades at a lower forward P/E (8.9x vs 14.7x for Gilead Sciences). Bristol-Myers Squibb offers the higher dividend yield (4.26% vs 2.22%). Gilead Sciences converts more of its revenue into profit, with a net margin of 28.9% versus 14.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMY | GILD |
|---|---|---|
| Share price | $58.93 | $144.93 |
| Market cap | $120.37B | $179.71B |
| 1-day change | -1.30% | -1.31% |
| YTD return | +10.68% | +19.64% |
| 1-year return | +33.68% | +25.75% |
| 5-year return | +2.30% | +117.14% |
| P/E ratio (TTM) | 12.98 | — |
| Forward P/E | 8.94 | 14.66 |
| EPS (TTM) | $4.54 | $-2.65 |
| Dividend yield | 4.26% | 2.22% |
| Annual dividend | $2.51 | $3.22 |
| Revenue (latest FY) | $48.19B | $29.44B |
| Revenue growth (YoY) | -0.22% | +2.40% |
| Net income (latest FY) | $7.05B | $8.51B |
| Gross margin | 71.08% | 78.83% |
| Operating margin | — | 34.04% |
| Net margin | 14.64% | 28.90% |
| 52-week high | $68.64 | $157.29 |
| 52-week low | $42.52 | $114.02 |
| Distance from 52-week high | -14.15% | -7.86% |
| Analyst consensus | hold | buy |
| Avg. price target upside | +12.30% | +9.89% |
| Average volume | 11.22M | 6.01M |
| Shares outstanding | 2.04B | 1.24B |
| Employees | 32,500 | 17,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Bristol-Myers Squibb offers a meaningfully higher dividend yield (4.26% vs 2.22%).
- Gilead Sciences is more profitable, keeping 28.9 cents of every revenue dollar as net income versus 14.6 cents for Bristol-Myers Squibb.
About Bristol-Myers Squibb
BMY stock →Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 32,500 employees
About Gilead Sciences
GILD stock →Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 17,000 employees
BMY vs GILD FAQ
Which is bigger, Bristol-Myers Squibb or Gilead Sciences?
Gilead Sciences (GILD) is larger, with a market capitalization of $179.71B compared with $120.37B for Bristol-Myers Squibb (BMY).
Which stock has performed better over the past year, BMY or GILD?
BMY returned +33.68% over the past 12 months, compared with +25.75% for GILD (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Bristol-Myers Squibb or Gilead Sciences?
Bristol-Myers Squibb has the higher yield at 4.26%, compared with 2.22% for Gilead Sciences.
Are Bristol-Myers Squibb and Gilead Sciences in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Bristol-Myers Squibb and Biotechnology: Biological Products (No Diagnostic Substances) for Gilead Sciences.